Latest news with #RetinAI
Yahoo
2 days ago
- Health
- Yahoo
Ethan Yan Featured in XYZ Media's 'Next Generation of Innovators' for RetinAI, an AI-Powered System Making Early Eye Cancer Detection Affordable and Accessible
LOS ANGELES, June 05, 2025 (GLOBE NEWSWIRE) -- XYZ Media, a leading media company that bridges educational pursuits with technological innovation, is thrilled to announce a new season of its 'Next Generation of Innovators' series, a digital campaign that casts a spotlight on the extraordinary young leaders shaping the future through inventive solutions to global challenges. This series proudly features Ethan Yan, a Groton School student whose innovation, RetinAI, significantly advances the early diagnosis of retinoblastoma, a childhood eye cancer, through an affordable, accessible, AI-powered screening system. Ethan developed RetinAI to support timely and accurate diagnoses, particularly in underserved regions with limited access to costly medical infrastructure. RetinAI consists of two primary parts: a wearable headset designed for external pupil imaging, and a handheld, non-mydriatic retinal camera. Both parts use advanced deep learning models that can detect leukocoria—a critical early symptom of retinoblastoma—along with direct identification of retinal tumors without the need for dilating the pupil. Designed to detect leukocoria as small as 1mm in diameter, RetinAI stands out as a powerful tool for early-stage tumor identification. 'When I was a child, I was diagnosed with retinoblastoma—but my primary doctor initially missed it,' Ethan said. 'I later learned that missed or delayed diagnoses are not uncommon. This experience became the motivation behind my project: to help other children with retinoblastoma receive earlier diagnoses and, in some severe cases, preserve their vision. By developing RetinAI, I hope to create a tool that ensures no child misses the chance for early care that could protect their vision.' Ethan has successfully completed early clinical testing of RetinAI. The system captured high-quality retinal images and was able to identify both normal anatomy and conditions such as retinoblastoma tumors, retinal detachment, hemangiomas, and macular degeneration. Built for accessibility, RetinAI's production cost is under $100—an extraordinary breakthrough compared to existing diagnostic devices that can cost over $200,000. 'I envision a future where RetinAI is integrated into routine health screenings: during annual checkups, school eye exams, and even at-home assessments,' Ethan said. 'With widespread use, every child with retinoblastoma could be diagnosed early—when the disease is most treatable—and receive timely care. My research aims to make that future a reality by providing an accessible, AI- powered tool that empowers both healthcare providers and families to detect this cancer before it causes irreversible harm.' 'Ethan embodies what it means to be a 'Next Generation Innovator' in the truest sense,' said Jordan Hayes, Director of Communications at XYZ Media. 'This is a brilliant young scientist, taking a personal experience from his childhood and turning it into a real-world solution with big potential. Ethan's project is a reminder of how resilience, compassion and creativity can make real changes.' Through the "Next Generation of Innovators" series, XYZ Media continues its commitment to celebrating young leaders turning bold ideas into impactful realities. About XYZ Media: Founded in 2018, XYZ Media is a media and marketing company that stands at the forefront of integrating educational initiatives with technological innovation, driving market trends, and shaping the digital landscape. XYZ Media is dedicated to spotlighting the achievements of tomorrow's leaders driving change. With a keen focus on educational excellence and digital innovation, XYZ Media fosters a community where young minds are encouraged to challenge the status quo and develop solutions for a better tomorrow. To learn more information on XYZ Media's 'Next Generation of Innovators' series, please contact: Jordan HayesDirector of Communicationspr@ Media21606 Devonshire Street, Los Angeles, CA Disclaimer: This content is provided by XYZ Media. The statements, views, and opinions expressed in this column are solely those of the content provider. The information shared in this press release is not a solicitation for investment, nor is it intended as investment, financial, or trading advice. It is strongly recommended that you conduct thorough research and consult with a professional financial advisor before making any investment or trading decisions. Please conduct your own research and invest at your own risk. A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Health
- Yahoo
Ethan Yan Featured in XYZ Media's 'Next Generation of Innovators' for RetinAI, an AI-Powered System Making Early Eye Cancer Detection Affordable and Accessible
LOS ANGELES, June 05, 2025 (GLOBE NEWSWIRE) -- XYZ Media, a leading media company that bridges educational pursuits with technological innovation, is thrilled to announce a new season of its 'Next Generation of Innovators' series, a digital campaign that casts a spotlight on the extraordinary young leaders shaping the future through inventive solutions to global challenges. This series proudly features Ethan Yan, a Groton School student whose innovation, RetinAI, significantly advances the early diagnosis of retinoblastoma, a childhood eye cancer, through an affordable, accessible, AI-powered screening system. Ethan developed RetinAI to support timely and accurate diagnoses, particularly in underserved regions with limited access to costly medical infrastructure. RetinAI consists of two primary parts: a wearable headset designed for external pupil imaging, and a handheld, non-mydriatic retinal camera. Both parts use advanced deep learning models that can detect leukocoria—a critical early symptom of retinoblastoma—along with direct identification of retinal tumors without the need for dilating the pupil. Designed to detect leukocoria as small as 1mm in diameter, RetinAI stands out as a powerful tool for early-stage tumor identification. 'When I was a child, I was diagnosed with retinoblastoma—but my primary doctor initially missed it,' Ethan said. 'I later learned that missed or delayed diagnoses are not uncommon. This experience became the motivation behind my project: to help other children with retinoblastoma receive earlier diagnoses and, in some severe cases, preserve their vision. By developing RetinAI, I hope to create a tool that ensures no child misses the chance for early care that could protect their vision.' Ethan has successfully completed early clinical testing of RetinAI. The system captured high-quality retinal images and was able to identify both normal anatomy and conditions such as retinoblastoma tumors, retinal detachment, hemangiomas, and macular degeneration. Built for accessibility, RetinAI's production cost is under $100—an extraordinary breakthrough compared to existing diagnostic devices that can cost over $200,000. 'I envision a future where RetinAI is integrated into routine health screenings: during annual checkups, school eye exams, and even at-home assessments,' Ethan said. 'With widespread use, every child with retinoblastoma could be diagnosed early—when the disease is most treatable—and receive timely care. My research aims to make that future a reality by providing an accessible, AI- powered tool that empowers both healthcare providers and families to detect this cancer before it causes irreversible harm.' 'Ethan embodies what it means to be a 'Next Generation Innovator' in the truest sense,' said Jordan Hayes, Director of Communications at XYZ Media. 'This is a brilliant young scientist, taking a personal experience from his childhood and turning it into a real-world solution with big potential. Ethan's project is a reminder of how resilience, compassion and creativity can make real changes.' Through the "Next Generation of Innovators" series, XYZ Media continues its commitment to celebrating young leaders turning bold ideas into impactful realities. About XYZ Media: Founded in 2018, XYZ Media is a media and marketing company that stands at the forefront of integrating educational initiatives with technological innovation, driving market trends, and shaping the digital landscape. XYZ Media is dedicated to spotlighting the achievements of tomorrow's leaders driving change. With a keen focus on educational excellence and digital innovation, XYZ Media fosters a community where young minds are encouraged to challenge the status quo and develop solutions for a better tomorrow. To learn more information on XYZ Media's 'Next Generation of Innovators' series, please contact: Jordan HayesDirector of Communicationspr@ Media21606 Devonshire Street, Los Angeles, CA Disclaimer: This content is provided by XYZ Media. The statements, views, and opinions expressed in this column are solely those of the content provider. The information shared in this press release is not a solicitation for investment, nor is it intended as investment, financial, or trading advice. It is strongly recommended that you conduct thorough research and consult with a professional financial advisor before making any investment or trading decisions. Please conduct your own research and invest at your own risk. A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
30-04-2025
- Health
- Associated Press
RetinAI and FVS Announce CE-MDR Certification for Co-developed AI-based Diabetic Retinopathy Screening Algorithm, LuxIA®
BERN, Switzerland and MADRID, April 30, 2025 (GLOBE NEWSWIRE) -- RetinAI US Inc. (RetinAI) and Fundación Ver Salud (FVS) are pleased to jointly announce that LuxIA®, their co-developed innovative AI algorithm for Diabetic Retinopathy (DR) screening, has successfully received CE-MDR certification as a Class IIb medical device under the European Union Medical Device Regulation (EU MDR 2017/745). The certification was granted through Ikerian AG, RetinAI's parent company. LuxIA is designed to screen adult diabetic patients for more-than-mild diabetic retinopathy (mtmDR). This indication for use provides critical support for ophthalmologists, general practitioners and trained healthcare professionals across the European Union to achieve an earlier diagnosis of mtmDR, a vision-threatening eye disease. This new certification demonstrates the strong collaboration between FVS and RetinAI, emphasizing both entities' commitment to deliver AI-driven tools that meet stringent regulatory standards and significantly enhance patient management and clinical outcomes. The device is indicated for processing digital 45-degree colour fundus images from NW200, NW400 or equivalent Topcon cameras, ensuring seamless placement into existing clinical workflows. Together with RetinAI's existing portfolio of AI-based OCT analysis solutions, LuxIA complements a comprehensive suite of clinically validated, CE-certified AI modules focused on ophthalmology. Dr. Carlos Ciller, CEO and co-founder of RetinAI, commented: 'Receiving CE-MDR certification for LuxIA underscores our shared commitment with FVS to advance leading-edge ophthalmic care to patients through reliable and impactful AI technology. This milestone is pivotal, enabling healthcare providers to improve patient management and outcomes for diabetic retinopathy across Europe, reinforcing our joint mission of transforming vision care through innovation.' Dr. Juan Donate, MD, President of Fundación Ver Salud stated: 'We are excited about the newly received certification and look forward to the significant impact LuxIA will have in the European ophthalmology market. AI-driven screening solutions are critical to improving patient care, and we anticipate LuxIA will play a central role in achieving this.' For further information or to request a demonstration of LuxIA and other ophthalmic solutions from FVS and RetinAI, please visit For further information please contact: At the company Carlos Ciller, PhD, CEO - Ikerian AG and RetinAI Inc US [email protected], [email protected] Media enquiries Sue Charles, Charles Consultants - [email protected] +44 (0)7968726585 About Ikerian AG and RetinAI Inc. US Established in 2017, Ikerian AG (formerly RetinAI Medical AG) and its subsidiary, RetinAI U.S. Inc. ('Ikerian', 'RetinAI' and, together, 'the company'), develops software solutions to accelerate clinical, research and pharmaceutical workflows globally using advanced machine learning and computer vision, across ophthalmology, neurodegenerative disorders, vascular conditions, and rare diseases. RetinAI builds tools to collect, organize and analyze health data from the eyes, enabling healthcare professionals to make the right decisions sooner in healthcare. RetinAI's international team leverages its clinical, technical, and scientific expertise to foster the transition from reactive to preventive medicine for severe eye diseases. Follow us on LinkedInand About FVS FVS is a non-profit organization focused on training, research, and medical innovation, particularly in the field of ophthalmology. Its mission is to develop solutions that promote better clinical outcomes and enhance the quality of patient care. Follow us on LinkedIn and X
